A Phase 2 Study of LY3209590 in Participants With Type 2 Diabetes Mellitus

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 278 participants.

Also called NCT04450394

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 278 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04450394
  • EudraCT 2019-003339-53
Other papers using this trial's data
  • Once-Weekly Basal Insulin Fc Demonstrated Similar Glycemic Control to Once-Daily Insulin Degludec in Insulin-Naive Patients With Type 2 Diabetes: A Phase 2 Randomized Control Trial Diabetes care, 2023-05-01 DOI, PubMed 36944059, PMC10154646 In the PMC Open Access subset under a licence that is not Creative Commons.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Germany, Poland, Puerto Rico (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04450394. Randomized; no masking; primary purpose treatment. Start 2020-07-01 (actual); primary completion 2021-10-08 (actual). Results posted on 2022-11-02.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase 2 Study of LY3209590 in Participants With Type 2 Diabetes Mellitus
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
LY3209590
Intervention (Drug)
Insulin Degludec
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct04450394
Content hash
d57b2509e4e9ba85c2bdc9d6611c72ddf3837bfc921505a2807a8a19549759f1